Sign in

MBX on Nasdaq

MBX Biosciences, Inc.

In its 2026 annual report the company says: “We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing.”3 It is headquartered in Carmel, Indiana.1 Its shares trade on Nasdaq under the symbol MBX.1

Price unavailable

Last updated Oct 21, 2026.

Overview

Compare with another stock.

  • TickerMBX on Nasdaq1
  • IndustryPharmaceutical Preparations1
  • HeadquartersCarmel, Indiana1
  • Incorporated inDE2
  • Business address11711 N. Meridian Street, Suite 300, Carmel, In 460322
  • Filer category, Emerging growth company2
  • Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide ™ ("PEP ™ ") platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients. Our PEPs are selectively engineered to have optimized pharmaceutical properties, including extended time-action profiles and consistent drug concentrations with low peak-to-trough concentration ratios, consistent exposure to target tissues, and less frequent dosing. We are advancing a pipeline of novel candidates for endo…3 From its latest annual report

Financials

From the company’s reports to the SEC. Every number links to the filing it came from.

Financial statements

Operating income45-$98.1M in 2025+178% since 2023
-$100.0M-$75.0M-$50.0M-$25.0M02023: -$35.3M-$35.3M20232024: -$68.2M-$68.2M2024+93%2025: -$98.1M-$98.1M2025+44%
Net income456-$87.0M in 2025+167% since 2023
-$100.0M-$75.0M-$50.0M-$25.0M02023: -$32.6M-$32.6M20232024: -$61.9M-$61.9M2024+90%2025: -$87.0M-$87.0M2025+40%

Every line of the income statement as filed: the last 2 fiscal years, latest first.5

Period ending2025-12-312024-12-31
Research and development$79.2M$57.4M
General and administrative$18.9M$10.8M
Total operating expenses$98.1M$68.2M
Loss from operations-$98.1M-$68.2M
Interest and other income, net$11.1M$6.3M
Net loss-$87.0M-$61.9M
Unrealized gain on marketable securities$285.0K$54.0K
Reclassification of net gains included in net loss-$54.0K-$59.0K
Total other comprehensive gain (loss)$231.0K-$5.0K
Total comprehensive loss-$86.7M-$61.9M
Net loss attributable to common stockholders-$87.0M-$61.9M
Net loss per common share, basic-$2.38-$5.82
Net loss per common share, diluted-$2.38-$5.82
Weighted average number of common shares outstanding used in computation of net loss per common share, basic36.5M shares10.6M shares
Weighted average number of common shares outstanding used in computation of net loss per common share, diluted36.5M shares10.6M shares

Compare MBX Biosciences, Inc. with another company

Corporate structure

MBX Biosciences, Inc. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Major holders of MBX Biosciences, Inc.

  • MBX Biosciences, Inc. Carmel, Indiana

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What MBX Biosciences, Inc. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Property and equipment

ItemLatestA year beforeChange
Property and equipment, before depreciation$3.4M5 Dec 31, 2025$1.5M5 Dec 31, 2024+126.7%
Accumulated depreciation$670.0K5 Dec 31, 2025$422.0K5 Dec 31, 2024+58.8%
Property and equipment, net$2.7M5 Dec 31, 2025$1.1M5 Dec 31, 2024+153.2%
Operating-lease assets (leased space)$487.0K5 Dec 31, 2025$119.0K5 Dec 31, 2024+309.2%

Investments

ItemLatestA year beforeChange
Cash and cash equivalents$75.3M5 Dec 31, 2025$49.4M5 Dec 31, 2024+52.6%
Marketable securities, current$298.4M5 Dec 31, 2025$212.8M5 Dec 31, 2024+40.2%
Debt securities available for sale$298.4M5 Dec 31, 2025$222.8M5 Dec 31, 2024+33.9%

Properties, in its own words

Our principal executive offices are located in Carmel, Indiana. We lease our office space, which consists of 8,260 square feet. Our lease expires on December 31, 2028, with the option to renew for an additional three-year period. We also lease 810 square feet of laboratory space in Indianapolis, Indiana, under a lease that expires on November 30, 2026, and we previously leased 1,580 square feet of laboratory space in Indianapolis, Indiana, under a lease that expired on December 31, 2025. In

February 2026, we entered into a lease for an additional 13,642 square feet laboratory and office space in Burlington, Massachusetts, which is expected to commence in May 2026. We believe our current facilities are sufficient to meet our needs until the expiration of our leases. To meet the future needs of our business, we may lease additional or alternate space. We believe that suitable additional or substitute space at commercially reasonable terms will be available as needed to accommodate any future expansion of our operations.

Item 2 of the 10-K filed Mar 12, 2026.3

Leadership

Who has led MBX Biosciences, Inc., and when. Pick a name to see everywhere that person has worked.

Chief executive

  1. P. Kent Hawryluk2024–2026
  2. Steven L. Hoerter2026–now

President

  1. P. Kent Hawryluk2024–2026
  2. Steven L. Hoerter2026–now

Chief financial officer

  1. Richard Bartram2024–2026
  2. John W. Smither2026–now
2025
Board members and other officers (11)

Named in SEC Form D filings

People the company listed in its private-offering notices.

  • Executive Officer, DirectorPeter Kent Hawryluk named Nov 18, 202222
  • Executive Officer, DirectorRichard Kent DiMarchi named Nov 18, 202222

Timeline

  1. Aug 27, 20268-K Regulation FD disclosure; Other events23
  2. Aug 6, 20268-K Results of operations; Regulation FD disclosure; Other events24
  3. Aug 4, 2026New chief executive Steven L. Hoerter becomes CEO8
  4. Jul 13, 20268-K Executive or director change25
  5. Jun 12, 20268-K Regulation FD disclosure; Other events26
  6. Jun 5, 20268-K Executive or director change; Shareholder vote27
  7. May 11, 20268-K Regulation FD disclosure; Other events28
  8. May 7, 20268-K Results of operations29
  9. Mar 12, 20268-K Results of operations30
  10. Mar 9, 20268-K Regulation FD disclosure; Other events31
  11. Feb 27, 20268-K Entered a material agreement; Executive or director change32
  12. Feb 5, 20268-K Other events33
  13. Jan 22, 20268-K Executive or director change; Regulation FD disclosure34
  14. Sep 12, 2024New chief executive P. Kent Hawryluk becomes CEO9

Calendar

Coming up

  1. Nov 5, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.63) a share, on Nov 6, 2025.35

When it reported results

  1. Aug 6, 2026Reported quarterly or annual results24
  2. May 7, 2026Reported quarterly or annual results29
  3. Mar 12, 2026Reported quarterly or annual results30
  4. Jan 12, 2026Reported quarterly or annual results36
  5. Nov 6, 2025Reported quarterly or annual results37
  6. Aug 7, 2025Reported quarterly or annual results38
  7. May 12, 2025Reported quarterly or annual results39
  8. Mar 17, 2025Reported quarterly or annual results40

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

223 filings to the SEC since October 2021: 2 annual reports, 6 quarterly reports, 27 major events, 95 insider forms, 31 large holders, 1 private raises, 61 other. The latest 20:

  1. Aug 27, 20268-K EDGAR
  2. Aug 17, 2026144 EDGAR
  3. Aug 14, 2026SCHEDULE 13G/A EDGAR
  4. Aug 10, 2026SCHEDULE 13D/A EDGAR
  5. Aug 10, 2026SCHEDULE 13D/A EDGAR
  6. Aug 6, 202610-Q EDGAR
  7. Aug 6, 20268-K EDGAR
  8. Aug 5, 20264 EDGAR
  9. Aug 4, 2026144 EDGAR
  10. Aug 4, 2026144 EDGAR
  11. Aug 4, 20264 EDGAR
  12. Aug 4, 20264 EDGAR
  13. Jul 29, 2026SCHEDULE 13G EDGAR
  14. Jul 13, 20268-K EDGAR
  15. Jul 8, 2026SCHEDULE 13G/A EDGAR
  16. Jul 8, 2026SCHEDULE 13G/A EDGAR
  17. Jun 24, 2026SCHEDULE 13G EDGAR
  18. Jun 12, 20268-K EDGAR
  19. Jun 10, 2026144 EDGAR
  20. Jun 9, 2026144 EDGAR

The 223 filings since October 2021 can be filtered by form type and year here when JavaScript is on.

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

29 open-market trades by officers, directors and large owners since October 2021: 25 buys and 4 sales. Grants, option exercises and gifts are left out.

DateWhoTradeSharesPriceValueFiling
Aug 4, 2026Azoulay SalomonChief Medical OfficerSale370$65.77$24.3KForm 4
May 8, 2026Azoulay SalomonChief Medical OfficerSale70,003$38.36$2.7MForm 4
May 6, 2026Azoulay SalomonChief Medical OfficerSale231$29.54$6.8KForm 4
May 6, 2026Hawryluk P. KentPresident & CEOSale607$29.54$17.9KForm 4
Mar 13, 2026Hawryluk P. KentPresident & CEOBuy18,500$28.41$525.6KForm 4
Oct 20, 2025Hawryluk P. KentPresident & CEOBuy20,000$13.64$272.8KForm 4
Oct 17, 2025Hoerter Steven L.President and CEOBuy20,000$13.25$265.0KForm 4
Sep 26, 2025FHMLS X, L.P.10% ownerBuy666,666$18.00$12.0MForm 4
Apr 8, 2025Pescovitz Ora H.DirectorBuy7,693$5.89$45.3KForm 4
Feb 18, 2025GORDON CARL LDirectorBuy143,170$10.84$1.6MForm 4
Feb 18, 2025OrbiMed Genesis GP LLCDirectorBuy143,170$10.84$1.6MForm 4
Feb 14, 2025GORDON CARL LDirectorBuy47,502$9.87$468.8KForm 4
Feb 14, 2025OrbiMed Genesis GP LLCDirectorBuy47,502$9.87$468.8KForm 4
Feb 4, 2025Hawryluk P. KentPresident & CEOBuy50,000$10.69$534.5KForm 4
Sep 16, 2024Mathers Edward TDirectorBuy500,000$16.00$8.0MForm 4
Sep 16, 2024BASKETT FOREST10% ownerBuy500,000$16.00$8.0MForm 4
Sep 16, 2024Behbahani Ali10% ownerBuy500,000$16.00$8.0MForm 4
Sep 16, 2024Chang Carmen10% ownerBuy500,000$16.00$8.0MForm 4
Sep 16, 2024Florence Anthony A. Jr.10% ownerBuy500,000$16.00$8.0MForm 4
Sep 16, 2024Makhzoumi Mohamad10% ownerBuy500,000$16.00$8.0MForm 4

All 29 trades can be filtered by person here when JavaScript is on.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

YearExecutiveAgeSalaryTotal pay
2025P. Kent Hawryluk57$625.0K$3.0M52
2025Richard Bartram$484.0K$1.5M52
2025Salomon AzoulayM.D.69$488.5K$1.5M52
2024Chief Medical Officer$234.4K$3.1M52
2024President and Chief Executive Officer$483.3K$2.2M52
2024Former Chief Financial Officer$442.0K$1.2M52

Money raised

Private offerings the company reported to the SEC on Form D.

  1. Nov 7, 2022Raised $46.7 million in a private offering of equity Form D: $115.2 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 100. Change is in shares since the quarter before.

FundSharesValueShare of the fundChange
Frazier Life Sciences Management, L.P.6,652,013$367.2M8.0%No change
Fmr LLC5,322,885$293.8M0.0%+2,386,201
Wellington Management Group Llp4,977,523$274.8M0.0%+1,785,699
NEA Management Company, LLC3,614,486$199.5M12.6%No change
Orbimed Advisors LLC3,428,736$189.3M3.6%−209,151
BlackRock, Inc.3,323,672$183.5M0.0%+382,266
Paradigm Biocapital Advisors LP2,508,015$138.4M2.6%New
Nvp Associates, LLC2,136,335$117.9M35.9%No change
Deep Track Capital, LP1,732,569$95.6M1.4%−1,025,000
Polar Capital Holdings Plc1,608,514$88.8M0.3%−13,672
Vanguard Capital Management LLC1,477,388$81.6M0.0%−204
Aaron Wealth Advisors LLC1,167,799$64.5M3.3%−377
Driehaus Capital Management LLC1,056,579$58.3M0.3%+38,367
Kynam Capital Management, LP934,799$51.6M2.9%No change
Woodline Partners LP900,092$49.7M0.2%+29
Eventide Asset Management, LLC873,492$48.2M0.6%−16,508
State Street Corp864,466$47.7M0.0%+77,258
Parkman Healthcare Partners LLC800,173$44.2M4.5%+136
Geode Capital Management, LLC773,072$42.7M0.0%+102,687
Braidwell LP710,880$39.2M1.5%−781,587
TCG Crossover Management, LLC650,000$35.9M0.9%No change
Cormorant Asset Management, LP550,000$30.4M1.6%−570,000
Soleus Capital Management, L.P.515,279$28.4M1.0%+336,382
Goldman Sachs Group Inc459,005$25.3M0.0%+1,060
Marshall Wace, Llp401,885$22.2M0.0%+339,182

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How MBX Biosciences, Inc. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

  • Name on EDGARMBX Biosciences, Inc.1
  • CIK0001776111
  • Employer ID (EIN)84-18828723
  • Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
  • Incorporated inDelaware3
  • Fiscal year endsDecember 311
  • Industry code (SIC)2834 Pharmaceutical Preparations1
  • SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
  • Business address11711 N. Meridian Street, Suite 300, Carmel, IN 460321
  • Phone31798931001
  • Shares outstanding48,160,096 as of Aug 3, 20266
  • Public float$237.3M as of Jun 30, 20253
  • AuditorErnst & Young LLP, Indianapolis, Indiana PCAOB ID 42; no auditor attestation of internal control over financial reporting3
  • On EDGAR sinceMay 10, 20191
  • Filings226 in all: 4 (68), 8-K (27), 3 (25), 144 (17), SCHEDULE 13G/A (11), CORRESP (8), SCHEDULE 13D/A (8), 10-Q (6)1
    All 33 form types

    UPLOAD (5), SC 13D (4), SC 13G (4), SCHEDULE 13G (4), D (3), DEFA14A (3), EFFECT (3), S-8 (3), 10-K (2), 4/A (2), ARS (2), DEF 14A (2), DRS (2), DRS/A (2), DRSLTR (2), S-1 (2), S-1/A (2), S-1MEF (2), 424B4 (1), 424B5 (1), 8-A12B (1), CERT (1), D/A (1), S-3 (1), S-3ASR (1)

  • Latest filingsAnnual report (10-K) Mar 12, 2026
    Quarterly report (10-Q) Aug 6, 2026
    Proxy statement (DEF 14A) Apr 22, 2026
    Latest 8-K (8-K) Aug 27, 2026

Securities registered for trading

ClassSymbolExchange
Common Stock, par value $0.0001 per shareMBXThe Nasdaq Global Select Market

From the cover page of the 10-K filed Mar 12, 2026 (Section 12(b) of the Exchange Act).3

Risk factors and legal proceedings

The risks MBX Biosciences, Inc. names in Item 1A of its 10-K filed Mar 12, 2026: 73 risks under these headings, as written.3

  • Risks related to financial position and need for capital
  • We have incurred significant losses since inception. We expect to incur losses for the foreseeable future and may never achieve or maintain profitability.
  • We have never generated revenue from product sales and may never become profitable.
  • We will need substantial additional funding. If we are unable to raise additional capital when needed on acceptable terms, or at all, we may be forced to delay, reduce, or terminate certain of our research and product development programs, future commercialization efforts or other operations.
  • Our short operating history may make it difficult for you to evaluate the success of our business to date and to assess our future viability.
  • Our future ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited.
  • Changes in tax laws or in their implementation or interpretation may adversely affect our business and financial condition.
  • The U.S. Congress, the Trump administration, or any new administration may make substantial changes to fiscal, tax, and other federal policies that may adversely affect our business
  • Risks related to our business and industry
  • Our business is highly dependent on the success of our product candidates. If we are unable to successfully complete clinical development, obtain regulatory approval for or commercialize one or more of our product candidates, or if we experience delays in doing so, our business will be materially harmed.
  • If we fail to discover, develop and commercialize other product candidates, or successfully build out our own internal discovery capacities, we may be unable to grow our business and our ability to achieve our strategic objectives would be impaired.
  • The successful development of pharmaceutical products is highly uncertain.
The other 63 risks
  • We may incur unexpected costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
  • Even if we complete the necessary preclinical studies and clinical trials, the marketing approval process is expensive, time-consuming and uncertain and may prevent us from obtaining approvals for the commercialization of our product candidates.
  • Our product candidates may cause undesirable side effects or have other properties that could delay or prevent their regulatory approval, limit the commercial profile of an approved label, or result in significant negative consequences following regulatory approval, if obtained.
  • If our clinical trials fail to replicate positive results from earlier preclinical studies or clinical trials conducted by us or third parties, we may be unable to successfully develop, obtain regulatory approval for or commercialize our product candidates.
  • Interim, topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data becomes available and are subject to audit and verification procedures that could result in material changes in the final data.
  • We may find it difficult to enroll patients in our future clinical trials given the limited number of patients who have the diseases some of our product candidates are intended to target. Additionally, we also compete for trial participants with other clinical trials for product candidates or commercially available products that are in the same areas as our product candidates. If we experience delays or difficulties in the enrollment of patients in clinical trials, our clinical development activities and our receipt of necessary regulatory approvals could be delayed or prevented.
  • Even if any of our product candidates receives regulatory approval, it may fail to achieve the degree of market acceptance by physicians, patients, third-party payors and others in the medical community necessary for commercial success, in which case we may not generate significant revenues or become profitable.
  • We face significant competition in an environment of rapid change, and there is a possibility that our competitors may achieve regulatory approval before us or develop therapies that are safer or more advanced or effective than ours, or that we are unable to compete with existing entities that have made substantial investment into novel treatments for disease, which may harm our financial condition and our ability to successfully market or commercialize any product candidates we may develop.
  • Due to the significant resources required for the development of our pipeline, and depending on our ability to access capital, we must prioritize the development of certain product candidates over others. Moreover, we may fail to expend our limited resources on product candidates or indications that may have been more profitable or for which there is a greater likelihood of success.
  • We currently have no commercial marketing and sales organization and have no experience as a company in commercializing products, and we may have to invest significant resources to develop these capabilities. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our products, we may not be able to generate product revenue.
  • If we do not achieve our projected development and commercialization goals in the timeframes we announce and expect, the development and commercialization of our product candidates may be delayed, and our business and results of operations may be harmed.
  • Risks related to regulatory, legal, and clinical trials
  • The regulatory approval processes of the FDA and comparable foreign authorities are lengthy, time-consuming and inherently unpredictable, and if we are ultimately unable to obtain regulatory approval for our product candidates, our business will be substantially harmed.
  • Our product candidates require specific shipping, storage, handling and administration, which in some cases, may require cold-chain logistics and subject our product candidates to risk of loss or damage if failures occur.
  • Any drug delivery device that we potentially use to deliver our product candidates may have its own regulatory, development, supply and other risks.
  • The FDA or comparable foreign regulatory authorities may disagree with our regulatory plan for our product candidates.
  • We may in the future conduct clinical trials for drug candidates outside the United States, and the FDA and comparable foreign regulatory authorities may not accept data from such trials.
  • Obtaining and maintaining regulatory approval of our product candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our product candidates in other jurisdictions.
  • While we may in the future seek designations for our product candidates with the FDA and comparable foreign regulatory authorities that are intended to confer benefits such as a faster development process, an accelerated regulatory pathway or regulatory exclusivity, there can be no assurance that we will successfully obtain such designations. In addition, even if one or more of our product candidates are granted such designations, we may not be able to realize the intended benefits of such designations.
  • We may be unsuccessful in obtaining or may be unable to maintain the benefits associated with Orphan Drug Designation, including the potential for market exclusivity.
  • Our relationships with healthcare providers and physicians and third-party payors will be subject to applicable anti-kickback, fraud and abuse and other healthcare laws and regulations, which could expose us to criminal sanctions, civil penalties, contractual damages, reputational harm and diminished profits and future earnings.
  • Coverage and reimbursement may be limited or unavailable in certain market segments for our product candidates, if approved, which could make it difficult for us to sell any product candidates profitably.
  • Ongoing healthcare legislative and regulatory reform measures may have a material adverse effect on our business and results of operations.
  • Off-label use or misuse of our product candidates may harm our reputation in the marketplace or result in injuries that lead to costly product liability suits.
  • Changes in the FDA, other government agencies or comparable foreign regulatory authorities could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
  • Inadequate funding for the FDA or other government agencies could hinder their ability to hire and retain key leadership and other personnel, prevent new products and services from being developed or commercialized in a timely manner or otherwise prevent those agencies from performing normal business functions on which the operation of our business may rely, which could negatively impact our business.
  • Failure to access or a significant delay in accessing animal research models may materially adversely affect our ability to advance our preclinical programs and successfully develop any product candidates, which could result in significant harm to our business.
  • Even if we receive regulatory approval of any product candidates, we will be subject to ongoing regulatory obligations and continued regulatory review, which may result in significant additional expense and we may be subject to penalties if we fail to comply with regulatory requirements or experience unanticipated problems with our product candidates.
  • We are and will continue to be subject to U.S. and certain foreign export and import controls, sanctions, embargoes, anti-corruption laws, and anti-money laundering laws and regulations. Compliance with these legal standards could impair our ability to compete in domestic and international markets. We can face criminal liability and other serious consequences for violations, which can harm our business.
  • If we or any contract manufacturers and suppliers we engage fail to comply with environmental, health, and safety laws and regulations, we could become subject to fines or penalties or incur costs that could have a material adverse effect on the success of our business.
  • Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including non-compliance with regulatory standards and requirements and insider trading.
  • Product liability lawsuits against us could cause us to incur substantial liabilities and could limit commercialization of any product candidates that we may develop.
  • Our internal computer and information technology systems, or those of our third-party vendors, collaborators, contractors, consultants or other third parties, may fail, become unavailable, or suffer cybersecurity incidents, compromises, or data breaches, loss or leakage of data and other disruptions, which could result in a material disruption of our product development programs, compromise confidential, sensitive or personal information related to our business or prevent us from accessing critical information, potentially exposing us to liability or otherwise adversely affecting our business.
  • Laws and regulations governing any international operations we may have in the future may preclude us from developing, manufacturing and selling certain product candidates we may identify outside of the United States and require us to develop and implement costly compliance programs.
  • We are subject to stringent and often unsettled laws, rules, regulations, policies, standards and contractual obligations related to data privacy and security and changes in such laws, rules, regulations, policies, standards and contractual obligations could adversely affect our business.
  • The use of new and evolving technologies, such as artificial intelligence ("AI") in our operations may require us to expend material resources and may present risks and challenges that can impact our business including by posing security and other risks to our confidential information, proprietary information and personal information, any of which may result in reputational harm and liability, or otherwise adversely affect our business.
  • Significant political, trade, regulatory developments, and other circumstances beyond our control, could have a material adverse effect on our financial condition or results of operations.
  • Risks related to third-party relationships
  • We are reliant on a license agreement with Indiana University Research and Technology Corporation.
  • We are dependent on third parties having accurately generated, collected, interpreted and reported data from certain preclinical studies and clinical trials that were previously conducted for our product candidates.
  • If conflicts arise between us and our collaborators or strategic partners, these parties may act in a manner adverse to us and could limit our ability to implement our strategies.
  • We may seek to establish collaborations and, if we are not able to establish them on commercially reasonable terms, we may have to alter our development and commercialization plans.
  • We rely on third parties to assist in conducting our clinical trials. If they do not perform satisfactorily, we may not be able to obtain regulatory approval or commercialize our product candidates, or such approval or commercialization may be delayed, and our business could be substantially harmed.
  • Changes in methods of product candidate manufacturing or formulation may result in additional costs or delay.
  • Our use of third parties to manufacture our product candidates may increase the risk that we will not have sufficient quantities of our product candidates, raw materials, active pharmaceutical ingredients ("APIs"), or drug products when needed or at an acceptable cost.
  • If any third-party manufacturer of our product candidates is unable to increase the scale of its production of our product candidates or increase the product yield of its manufacturing, then our manufacturing costs may increase and commercialization may be delayed.
  • We may need to maintain licenses for APIs from third parties to develop and commercialize some of our product candidates, which could increase our development costs and delay our ability to commercialize those product candidates.
  • Risks related to personnel, operations, and growth
  • We are dependent on the services of our management and other clinical and scientific personnel, and if we are not able to retain these individuals or recruit additional management or clinical and scientific personnel, our business will suffer.
  • We will need to continue to significantly increase the size of our organization and we may have difficulties in managing our growth and expanding our operations successfully.
  • Risks related to our intellectual property
  • Our commercial success depends on our ability to obtain, maintain, enforce, and otherwise protect our intellectual property and proprietary technology, and if the scope of the intellectual property protection obtained is not sufficiently broad, our competitors or other third parties could develop and commercialize products and product candidates similar to ours and our ability to successfully develop and commercialize our product candidates may be adversely affected.
  • If we fail to comply with our obligations in the agreements under which we license intellectual property rights from third parties or otherwise experience disruptions to our business relationships with our current and future licensors, we could lose license rights that are important to our business.
  • It is difficult and costly to protect our intellectual property and our proprietary technologies, and we may not be able to ensure their protection.
  • Patent terms may be inadequate to protect our competitive position on our products for an adequate amount of time.
  • Changes in the interpretation of patent law in the United States and other jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products.
  • We may not be able to seek or obtain patent protection throughout the world or enforce such patent protection once obtained.
  • In order to protect our competitive position around our product candidates, we may become involved in lawsuits to enforce our patents or other intellectual property, which could be expensive, time consuming and unsuccessful and which may result in our patents being found invalid or unenforceable.
  • If we are sued for infringing intellectual property rights of third parties, such litigation could be costly and time consuming and could prevent or delay us from developing or commercializing our product candidates.
  • Others may challenge inventorship or claim an ownership interest in our intellectual property which could expose it to litigation and have a significant adverse effect on its prospects.
  • We may be subject to claims that we have wrongfully hired an employee from a competitor or by third parties asserting that our employees or we have misappropriated their intellectual property or claiming ownership of what we regard as our own intellectual property.
  • We may rely on trade secrets and proprietary know-how which can be difficult to trace and enforce and, if we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed.
  • We may need to acquire or license additional intellectual property from third parties, and such licenses may not be available or may not be available on commercially reasonable terms.
  • If our trademarks and trade names are not adequately protected, then we may not be able to build name recognition in our trademarks of interest and our business may be adversely affected.
  • Intellectual property rights do not necessarily address all potential threats to our business.
  • Risks Related to Ownership of Our Common Stock
  • The market price of our common stock may be volatile, which could result in substantial losses for our shareholders.
  • We incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives and corporate governance practices.

Legal proceedings

From time to time, we may become involved in litigation or legal proceedings. We are not currently a party to any litigation or legal proceedings that, in the opinion of our management, are probable to have a material adverse effect on our business. Regardless of outcome, litigation can have an adverse impact on our business, financial condition, results of operations and prospects because of defense and settlement costs, diversion of management resources and other factors.

The opening of Item 3, Legal Proceedings.3

Sources

The numbers on this page point here. Each one links to the record it came from.

  1. 1
  2. 2
  3. 3
  4. 4
  5. 5
  6. 6
  7. 7
  8. 8
  9. 9
  10. 10
  11. 11
  12. 12
  13. 13
  14. 14
  15. 15
  16. 16
  17. 17
  18. 18
  19. 19
  20. 20
  21. 21
  22. 22
  23. 23
  24. 24
  25. 25
  26. 26
  27. 27
  28. 28
  29. 29
  30. 30
  31. 31
  32. 32
  33. 33
    SEC EDGAROther events
  34. 34
  35. 35
  36. 36
  37. 37
  38. 38
  39. 39
  40. 40
  41. 41
  42. 42
  43. 43
  44. 44
  45. 45
  46. 46
  47. 47
  48. 48
  49. 49
  50. 50
  51. 51
  52. 52